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ABSTRACT 
 
Objectives: On transrectal ultrasound (TRUS), prostate cancers are visualized as hypoechoic or 
isoechoic lesions. The incidence of hyperechoic lesions considered as cancer has been reported to be 
approximately 1.5%. The aim of the study was to estimate the incidence of TRUS hyperechoic 
lesions and of hyperechoic prostate cancer in TRUS guided biopsy specimens. 
 methods: We prospectively studied 200 patients with total PSA <20 ng/mL and/or positive digital 
rectal examination who had undergone TRUS guided prostate biopsy. Each patient underwent 
laterally directed systemic six-core biopsy plus cores from abnormal TRUS lesions and rectally 
palpable lesions. Six to ten biopsy cores were obtained from each patient. 
Results: Hyperechoic lesions were found in 19 (9.5%), hypoechoic in 83 (41.5%) and isoechoic in 
98 (49.0%) patients. Prostate cancer was diagnosed in 33.0% of study patients. Isoechoic findings on 
TRUS were recorded in 31.8% of patients diagnosed with prostate cancer, while 60.6% of cancers 
had hypoechoic and 7.6% hyperechoic lesions. There was no significant difference in the mean 
Gleason score between isoechoic cancers (mean 5.4) and hypoechoic cancers (mean 5.6). However, 
hyperechoic cancers had a mean Gleason score of 7.0, which was higher when compared with 
isoechoic and hypoechoic cancers. 
Conclusion: Biopsy of hyperechoic lesions was positive for prostate cancer in a higher percentage of 
patients than previously reported in the literature, and Gleason score of these cancers was higher 
when compared with isoechoic and hypoechoic cancers. 
Key words: prostate biopsy; transrectal ultrasound; hyperechoic lesions; prostate cancer 
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INTRODUCTION 
 
Prostate cancer is a very common entity, with the incidence increasing with age. The 
majority of these patients are free from symptoms and less than 3% of patients with 
pathologically confirmed diagnosis die from prostate cancer.1  The introduction of transrectal 
ultrasound (TRUS) probe by Wantanabe et al.2 and development of the diagnostic procedure first 
applied in 1981 by Holm and Gammelgard3 have significantly contributed to the early diagnosis 
of prostate cancer. Besides having a major role in positioning the needle trajectory for prostate 
biopsy, TRUS enables visualization of focal lesions suspected of prostate cancer.4-8 A definitive 
protocol regarding the number of biopsy cores for prostate biopsy has not yet been established, 
and the number of cores taken per biopsy varies from 4 to 30.9-11 Recently, the average number 
of biopsies has been gradually increasing, however, the detection rate remains unchanged and the 
need of repeat biopsy is increasing. Despite the high rate of false negative biopsy findings (20-
30%), as reported by Rabbani et al.12 and Fleshner and al.13, sextant biopsies are still in wide 
use.14,15 Hyperechoic lesions are usually considered as benign, whether benign prostate 
hyperplasia (BPH), prostatitis or prostate infarction.8 On TRUS, prostate cancer is visualized as a 
hypoechoic lesion in 60-70%, and as isoechoic lesion in 30-40% of cases. Hyperechoic lesions 
are rare, with an incidence of approximately 1.5%.16-19 Some unusual types of prostatic 
adenocarcinoma have been reported to appear as hyperechoic lesions, e.g., in case of ductal 
adenocarcinoma with central necrosis, dysmorphic calcifications and deposition of intraluminal 
crystals.16 The aim of this study was to estimate the incidence of TRUS hyperechoic lesions and 
of hyperechoic prostate cancer in TRUS guided biopsy specimens.    
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PATIENTS AND METHODS 
 
 This prospective study included a series of 200 patients with total PSA <20 ng/mL and/or 
positive digital rectal examination (DRE), age range 54-78 (mean 67.5) years, PSA 2.4-19.3 
(mean 9.9) ng/mL, and prostate volume 16-78 (mean 37.4) ccm.  
All study patients served as both experimental and control group. Each patient underwent 
TRUS and biopsy. Suspect lesions found on TRUS were classified as hypo- or hyperechoic. 
Mixed lesions were considered as hypoechoic TRUS findings.  
All patients underwent TRUS guided prostate biopsy and histopathologic findings were 
compared with TRUS findings.  
We used a Siemens SI-400 ultrasound device with biplane transrectal probe Siemens 
5,0/7,5 MHz  type 5727 LE 888. Biopsy was performed by an automatic Magnum gun with 
selective penetration of 15 or 22 mm, Magnum biopsy needle of 250 mm in length with 18 gauge 
and sampling needle of 19 mm in length. The procedures were performed on an outpatient basis. 
Patients took laxatives for one day and fluoroquinolone therapy for five days prior to biopsy, as 
recommended by Webb and Woo20 and Sieber et al.21 Transrectal ultrasound and biopsy were 
performed in standard position without anesthesia. DRE was performed first, followed by the 
measurement of prostate volume. Ultrasound was performed in detailed fashion, starting from 
the apex to the base. Biopsy was performed in sagittal view. The number of biopsies was 
determined according to DRE and ultrasound findings. If both were negative, six biopsy cores 
were obtained from the apex laterally, mid-laterally and base-laterally from both lobes. If hypo- 
or hyperechoic lesions were found, additional ultrasound guided biopsies were done from those 
lesions. Cores from these areas were inked on distal margin, and submitted on pathology in 
accordingly marked, separate container thus provided correct correlation between TRUS 
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and pathological findings. Only patients with positive cores obtained from hypo- or 
hyperechoic TRUS lesions were included in hypo- or hyperechoic group.  Biopsies were also 
obtained from areas appearing abnormal on DRE.  
An improved pre-embedding method for all biopsy specimens was applied, as described 
by Rogatsch et al.22 Specimens were fixed in 10% buffered formaldehyde, embedded in paraffin, 
cut at 5 µm thickness, and routinely stained with haematoxylin and eosin. In some cases, the 
material was stained with p63, HMW-CK and alcian-PAS. Alcian-PAS positive staining was not 
used as the only criterion since it is well known that such positivity might be seen in mimickers 
of cancer such as atrophy and adenosis.  
Statistical analysis was performed using χ2-test and Student's t-test. The level of 
significance was set at p<0.05. 
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RESULTS 
 
Results of PSA and TRUS findings in 200 patients were given in Table 1. One 
hundred and twenty (51.0%) patients had abnormal TRUS findings; 83 (41.5%) had hypoechoic 
lesions and 19 (9.5%) had hyperechoic lesions. The remaining 98 (49.0%) patients had isoechoic 
findings. Forty six (23.0%) patients had abnormal DRE, out of them 26 (56.5%) had 
normal PSA. TRUS in patients with positive DRE revealed 14 (30.4%) hypoechoic and 3 
(6.5%) hyperechoic lesions. A total of 1539 biopsies were done with 6-10 cores (mean 7.6) per 
patient and prostate cancer was diagnosed in 66 (33.0%) patients. Nine (0.58%) biopsy 
specimens were excluded from the study due to inadequate tissue for appropriate microscopic 
analysis. Isoechoic lesions were recorded in 21 (31.8%), hypoechoic lesions in 40 (60.6%), and 
hyperechoic lesions in five (7.6%) patients with prostate cancer (Table 2, Figure 1).  
In patients with hyperechoic carcinoma, a total of 43 (mean 8.6) biopsy cores were 
obtained, including 30 (69.8%) cores from peripheral zone and 13 (30.2%) from transitional 
zone. There were 14 (32.6%) (ranged from 2 to 4 per patients, mean 2.8) cancer positive cores, 
including 9 (64.0%) in peripheral zone and 5 (36.0%) in transitional zone. 
Overall, prostate cancer was detected in 26.3% of patients with TRUS hyperechoic 
lesions. In other hyperechoic lesions, the diagnosis of prostatic hyperplasia suggested (26.3%) 
and prostatitis was found in 47.4% of cases. Biopsies of TRUS visible focal lesions detected a 
significantly higher number of prostate cancers (68.2 %) when compared to TRUS negative 
prostate biopsies (31.8%) (p=0.001).  
The mean value of PSA was 10.1 ng/mL (ranged from 3.4 to 17.4) in patients with focal 
lesions and 9.8 ng/mL (ranged from 2.4 to 19.3) in patients with normal TRUS finding. In 
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patients with hyperechoic carcinoma the mean value of PSA was 10.2 ng/mL (ranged from 5.4 to 
16.5), in patients with hypoechoic carcinoma was 10.5 ng/mL (ranged from 3.8 to 16.3) and in 
patients with isoechoic carcinoma was 10.3 ng/mL (ranged from 3.6 to 19.3). The mean prostate 
volume was 38.2 ccm (ranged from 18 to 77) in patients with abnormal TRUS and 36.4 ccm 
(ranged from 16 to 78) in patients with normal TRUS. In patients with hyperechoic carcinoma 
the mean prostate volume was 36.6 ccm (ranged from 22 to 68), in patients with hypoechoic 
carcinoma was 37.2 ccm (ranged from 18 to 73), and in patients with isoechoic carcinoma 37.5 
ccm (ranged from 19 to 69). Statistical analysis showed no significant difference in PSA value 
and prostate volume between the analyzed groups (p>0.05).  
The mean Gleason score in isoechoic, hyperechoic and hypoechoic cancers was 5.4 
(ranged from 4 to 9), 5.6 (ranged from 5 to 9) and 7.0 (ranged from 6 to 9), respectively. There 
was no statistically significant difference in Gleason score between isoechoic and hypoechoic 
cancers (p>0.05). In hyperechoic tumors, Gleason score was higher as compared with the other 
two groups; however, the number of patients in the hyperechoic group was too small for 
statistical analysis (Table 2). 
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COMMENT 
It is believed that TRUS guided biopsy is the only accurate preoperative method for early 
diagnosis of prostate cancer. The average number of biopsies has been gradually increasing, 
however, sextant biopsies are still widely used.14,15 
In our study, hypoechoic lesions were found in 41.5% and hyperechoic lesions in 9.5% of 
patients. Forty nine percent of the patients had normal findings on transrectal ultrasound.  
We diagnosed cancer in 66 (33.0%) patients; 68.2% of them had focal lesions on TRUS, 
while 31.8% had normal ultrasound findings. In our study, the number of diagnosed cancers with 
abnormal TRUS was moderately higher as compared with the study conducted by Vo et al.23 that 
diagnosed 62.9% of prostate cancers in patients with abnormal TRUS findings and PSA >4. 
Finne et al.24 studied 200 patients with median PSA value of 13.2 ng/mL and found carcinoma in 
26% of patients. We diagnosed a higher number of carcinomas than Finne at al.24, where median 
PSA value was higher than that recorded in our study (13.2 vs. 9.9 ng/mL). Loch et al.7 report on 
a 29% rate of prostate cancer in patients with PSA >4. The patients included in their study had 
no limited PSA value. In our study, all patients had PSA <20, and we diagnosed a higher 
percentage of prostate cancers compared to Loch et al.7 The higher percentage of cancer detected 
in our study could probably be ascribed to additional biopsies that were obtained in hyperechoic 
lesions, where another five carcinomas were identified.  
There was no statistically significant correlation between serum PSA values and 
ultrasound findings. The mean PSA value in patients with abnormal TRUS findings was almost 
the same as the mean value recorded in patients with normal ultrasound findings (10.1 ng/mL vs. 
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9.8 ng/mL). Also, we found no significant difference between PSA value in hyperechoic, 
hypoechoic and isoechoic carcinoma. 
Review of the literature shows very rare findings of prostate cancer originating in 
hyperechoic lesions. The reported incidence is 1-1.5%.16-19 Egawa et al.16 performed transrectal 
ultrasonography prior to radical prostatectomy in 157 patients with prostate cancer and 
hyperechoic cancers were diagnosed in only two (1.3%) patients. Shinohara et al.17 diagnosed 70 
carcinomas, of which only one was hyperechoic (1.4%). Malika et al.18 performed biopsy in 100 
patients suspected of carcinoma and diagnosed 23 carcinomas, none of which was hyperechoic. 
They also found and submitted to biopsy 11 hyperechoic lesions but none of them was diagnosed 
as carcinoma. Stilmant and Kuligowska19 report on only one prostate cancer originating from a 
hyperechoic lesion. Our findings in 19 patients with hyperechoic lesions, five of them with 
diagnosed carcinoma (7.6% of all diagnosed carcinomas in our study) indicated a higher rate of 
hyperechoic cancers than that reported in the literature.16-19 Of the 5 patients with hyperechoic 
cancer, 3 underwent radical prostatectomy, which confirmed diagnosis, 1 was treated with 
radiation therapy and 1 recived androgen ablation therapy.  
Ellis and Brawer25 confirmed that Gleason score was independent of ultrasound findings, 
but biopsies were done on hypoechoic lesions. In our study, the mean Gleason score of 
carcinoma in patients with hypoechoic lesions and normal ultrasound findings was not 
significantly different, but carcinomas in patients with hyperechoic lesions had a higher mean 
Gleason score. Distribution of Gleason score in patients with hyperechoic carcinoma was 
equal to or greater than the median for all patients together (n = 66). In patients with 
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isoechoic and hypoechoic carcinoma, an approximately equivalent number of patients was 
distributed below and above the median. 
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         CONCLUSIONS  
Based on our study, we concluded that hyperechoic lesions were positive for prostate 
cancer in a higher percentage of patients than previously reported in the literature and suggest 
that additional biopsy of hyperechoic lesions be included in the protocol for prostate biopsy. This 
procedure, which includes a greater number of cores is well tolerated, has a minimal rate of 
complications, and should be part of the standard protocol in urological practice.26,27 
Additional studies are needed to determine the exact rate of hyperechoic cancer and the 
respective Gleason score. 
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Figure 1. Hyperechoic lesion in peripheral and transitional zone (volume of the prostate 1.2 
ccm). Biopsy revealed a high grade prostatic adenocarcinoma (Gleason score 8 (4+4). 
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Table 1. Results of PSA and TRUS findings in 200 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRUS PSA isoechoic hyperechoic hypoechoic Total 
< 4.0 10  (5.0%) 
2  
(1.0%) 
14  
(7.0%) 
26 
(13.0%) 
4.01 - 10.0 43  (21.5%) 
8 
(4.0%) 
29 
(14.5%) 
80 
(40.0%) 
10.01 – 20.0 45  (22.5%) 
9 
(4.5%) 
40 
(20.0%) 
94 
(47.0%) 
Total 98  (49.0%) 
19 
(9.5%) 
83 
(41.5%) 
200 
(100%) 
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Table 2. Transrectal ultrasound (TRUS) findings in diagnosed carcinomas (n=66) and mean 
Gleason score  
 
 
 
 
 
Number of cases 
 
Gleason score 
 
Isoechoic carcinoma 
(n=21) 
 
21 (31.8%) 
 
5.4 
 
Hypoechoic carcinoma 
(n=40) 
 
40 (60.6%) 
 
5.6 
 
Hyperechoic carcinoma 
(n=5) 
 
5 (7.6%) 
 
7.0 
